Contribution of radioiodine uptake measurement and thyroid scintigraphy to the differential diagnosis of thyrotoxicosis

Hellenic Journal of Nuclear Medicine

Volumn 13, Issue 2, 2010, Pages 132-137

  AlSharif, Abedallatif A ^a   Abujbara, Mousa A ^b   Chiacchio, Serena ^c   Ajlouni, Kamel M ^b   Mariani, Giuliano ^c  

^a UNIVERSITY OF JORDAN   (Jordan)

^b National Center for Diabetes Endocrinology and Genetics Jordan   (Jordan)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Hyperthyroidism; Overt thyrotoxicosis; Radioiodine scintigraphy; Radioiodine uptake measurement; Subclinical hyperthyroidism

Indexed keywords

IODINE 131;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL EVALUATION; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; THYROID SCINTISCANNING; THYROIDITIS; THYROTOXICOSIS; TOXIC GOITER;

ADOLESCENT; ADULT; AGED; BIOLOGICAL TRANSPORT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYROID GLAND; THYROTOXICOSIS; YOUNG ADULT;

EID: 77956353410     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cooper DS. Hyperthyroidism. Lancer 2003; 36: 459-68.
2. Pearce EN. Diagnosis and management of thyrotoxicosis. BMJ 2006; 332(7554): 1369-73.
3. Pearce EN. Diagnosis and management of thyrotoxicosis. BMJ 2006; 332: 1369-73.
4. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29: 76-131.
5. Weetman AP. Graves' disease. N Engl J Med 2000; 343: 1236-48.
6. Baskin HJ, Cobin RH, Duick DS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8: 457-69.
7. Summaria V, Salvatori M, Rufini V et al. Diagnostic imaging in thyrotoxicosis. Rays 1999; 24: 273-300.
8. Becker D, Charles ND, Dworkin H et al. Procedure guideline for thyroid scintigraphy. J Nucl Med 1996; 37: 1264-6.
9. Intenzo CM, dePapp AE, Jabbour S et al. Scintigraphic manifestations of thyrotoxicosis. Radiographics 2003; 23: 857-69.
10. Hollowell JG, Staehling NW, Flanders WD et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988-1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-99.
11. Laurberg P, Pedersen IB, Knudsen N et al.Environmental iodine intake affects the type of nonmalignant thyroid disease. Thyroid 2001; 11: 457-69.
12. Mittra ES, Niederkohr RD, Rodriguez C et al. Uncommon causes of thyrotoxicosis. J Nucl Med 2008; 49: 265-78.
13. Toft AD. Clinical practice: subclinical hyperthyroidism. N Engl J Med 2001; 345: 512-6.
14. Helfand M, Redfern CC. Clinical guideline, part 2: screening for thyroid disease; an update. American College of Physicians. Ann Intern Med 1998; 129: 144-58.
15. Sawin CT, Geller A, Wolf PA et al. Low serum thyrotropin concentration as a risk factor for atrial fibrillation in older patients. N Engl J Med 1994; 331: 1249-52.
16. Biondi B, Fazio S, Cuocolo A et al. Impaired cardiac reserve and exercise capacity in patients receiving longterm thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1996; 81: 4224-8.
17. Biondi B, Palmieri EA, Fazio S et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000; 85: 4701-5.
18. Surks MI, Ortiz E, Daniels GH et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-38.
19. Tollin SR, Fallon EF, Mikhail M et al. The utility of thyroid nuclear imaging and other studies in the detection and treatment of underlying thyroid abnormalities in patients with endogenous subclinical thyrotoxicosis. Clin Nucl Med 2000; 25: 341-7. (Pubitemid 30226863)
20. Ross DS. Subclinical thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the Thyroid: a fundamental and clinical text. 8th edn. Philadelphia: Lippincott, Williams and Wilkins N. Y.; 2000: 1016-20.
21. Papi G, Pearce EN, Braverman LE et al. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only. Am J Med 2005; 118: 349-61.
22. Biondi B, Palmieri EA, Klain M et al. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 2005; 152: 1-9. (Pubitemid 40185448)
23. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109-42.
24. Kasagi K, Takeuchi R, Misaki T et al. Subclinical Graves' disease as a cause of subnormal TSH levels in euthyroid subjects. J Endocrinol Invest 1997; 20: 183-8.
25. Stott DJ, McLellan AR, Finlayson J et al. Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at increased risk of developing overt hyperthyroidism. Q J Med1991; 78: 77-84.
26. Charles ND. The many causes of subclinical hyperthyroidism. Thyroid 1996; 6: 391-6.